TrialJBMR plus2022

Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia.

Iris R Hartley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.